Ventricular Tachycardia-Pipeline Review, H1 2017

Ventricular Tachycardia-Pipeline Review, H1 2017


  • Products Id :- GMDHC9303IDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ventricular Tachycardia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia-Pipeline Review, H1 2017, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.

Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness of breath. Causes include cardiomyopathy, ischemic heart disease and heart failure. Risk factors include age, family history and medical history. Treatment includes antiarrhythmic medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 3 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Ventricular Tachycardia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ventricular Tachycardia (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ventricular Tachycardia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ventricular Tachycardia (Cardiovascular)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ventricular Tachycardia-Overview

Ventricular Tachycardia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ventricular Tachycardia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ventricular Tachycardia-Companies Involved in Therapeutics Development

Armetheon Inc

Audentes Therapeutics Inc

Gilead Sciences Inc

HUYA Bioscience International LLC

InCarda Therapeutics Inc

Milestone Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Ventricular Tachycardia-Drug Profiles

aladorian sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-307-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

budiodarone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etripamil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flecainide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-967-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBI-3000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

landiolol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ventricular Tachycardia-Dormant Projects

Ventricular Tachycardia-Discontinued Products

Ventricular Tachycardia-Product Development Milestones

Featured News & Press Releases

May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia

Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions

Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer

Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias

Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients

Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Ventricular Tachycardia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Ventricular Tachycardia, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Ventricular Tachycardia-Pipeline by Armetheon Inc, H1 2017

Ventricular Tachycardia-Pipeline by Audentes Therapeutics Inc, H1 2017

Ventricular Tachycardia-Pipeline by Gilead Sciences Inc, H1 2017

Ventricular Tachycardia-Pipeline by HUYA Bioscience International LLC, H1 2017

Ventricular Tachycardia-Pipeline by InCarda Therapeutics Inc, H1 2017

Ventricular Tachycardia-Pipeline by Milestone Pharmaceuticals Inc, H1 2017

Ventricular Tachycardia-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Ventricular Tachycardia-Dormant Projects, H1 2017

Ventricular Tachycardia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Armetheon Inc, Audentes Therapeutics Inc, Gilead Sciences Inc, HUYA Bioscience International LLC, InCarda Therapeutics Inc, Milestone Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd

Ventricular Tachycardia Therapeutic Products under Development, Key Players in Ventricular Tachycardia Therapeutics, Ventricular Tachycardia Pipeline Overview, Ventricular Tachycardia Pipeline, Ventricular Tachycardia Pipeline Assessment

select a license
Single User License
USD 2000 INR 143800
Site License
USD 4000 INR 287600
Corporate User License
USD 6000 INR 431400

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com